The new study, published as an open-access original article in Cellular and Molecular Life Sciences, focuses on a chemical tag known as N6-methyladenosine, or m6A, the most abundant internal modification found in messenger RNA molecules across eukaryotic cells. Far from being decorative, m6A marks act as a dynamic layer of gene regulation: they influence how efficiently a transcript is translated into protein, how long it survives before being degraded, and even where it localizes within the cell. Writers install the mark, readers interpret it, and erasers remove it. The enzyme at the heart of the new findings, alkylation repair homolog protein 5, better known as ALKBH5, belongs to this last category. It is a demethylase, an enzyme that chemically strips m6A marks from RNA, and previous work had implicated it in everything from spermatogenesis to cancer progression. Whether it played any role in the diseased placenta, however, was unknown.

To find out, the researchers began where the disease begins: in placental tissue. Analyzing clinical samples from patients with preeclampsia, they discovered that ALKBH5 was consistently upregulated in the placentas of affected mothers compared with healthy pregnancies. Crucially, this overabundance of the demethylase coincided with a global decrease in m6A levels across placental transcripts, exactly what one would expect if an RNA eraser were working overtime. The same pattern appeared in a mouse model of preeclampsia-like disease, strengthening the case that the observation was not a human-tissue artifact but a reproducible feature of the disorder. The correlation, while compelling, left open the central question of causation: was ALKBH5 merely a bystander in the stressed placenta, or was it actively driving the pathology?

The team turned to a laboratory workhorse to answer that question. HTR8/SVneo cells, an immortalized human trophoblast line widely used to model placental cell behavior, were exposed to hydrogen peroxide to induce oxidative stress, mimicking the hostile environment that trophoblasts face in a preeclamptic placenta. As anticipated, the stressed cells lost their ability to invade and migrate, the very functions that healthy trophoblasts must perform to anchor the placenta and remodel maternal spiral arteries. But when the researchers knocked down ALKBH5 using small interfering RNA, the damage was partially reversed. The treated cells recovered a significant portion of their invasive and migratory capacity, suggesting that ALKBH5 was not simply responding to stress but actively contributing to the functional collapse of trophoblasts under oxidative assault.

With a functional link established, the next challenge was to identify the molecular target through which ALKBH5 exerted its effects. The researchers performed an integrated bioinformatics analysis, cross-referencing the RM2Target database with Gene Expression Omnibus datasets to search for genes that were both regulated by ALKBH5 and relevant to trophoblast biology. The search converged on a single compelling candidate: formyl peptide receptor 2, or FPR2, a G-protein-coupled receptor known to participate in inflammatory signaling. Subsequent validation experiments, including RNA immunoprecipitation and dual-luciferase reporter assays, confirmed that ALKBH5 physically and functionally interacts with FPR2 messenger RNA, establishing FPR2 as a bona fide downstream target of the demethylase.

The mechanistic details that emerged are elegant and, in the context of pregnancy disease, genuinely novel. ALKBH5 binds to the 3′ untranslated region of the FPR2 transcript, the stretch of RNA that follows the protein-coding sequence and typically governs transcript stability. By erasing m6A marks at this location, ALKBH5 stabilizes the FPR2 mRNA, allowing it to persist longer in the cell and driving up the production of the FPR2 receptor protein. In other words, the demethylase does not change the genetic message itself; it changes how long the message survives, and in doing so it amplifies a receptor that ultimately undermines trophoblast behavior. This m6A-dependent stabilization mechanism illustrates how epitranscriptomic regulation, a field barely two decades old, can produce consequences as dramatic as a pregnancy disorder.

The functional experiments sealed the argument. When the researchers overexpressed FPR2 in trophoblasts that had been protected by ALKBH5 knockdown, the protective effect vanished: the cells once again lost their invasive and migratory prowess under oxidative stress. FPR2, it appeared, was the executioner carrying out the damage that ALKBH5 had set in motion. Conversely, when the team administered WRW4, a pharmacological antagonist of FPR2, to mice with preeclampsia-like features, the disease phenotype improved. The antagonist ameliorated the key characteristics of the disorder in the animal model, providing proof of principle that blocking the receptor downstream of ALKBH5 can counteract the pathological process in a living system.

Taken together, the findings define what the authors describe as an ALKBH5–FPR2 axis in preeclampsia pathogenesis: an RNA-erasing enzyme upregulated in the diseased placenta strips methylation marks from FPR2 transcripts, prolongs their half-life, boosts receptor expression, and thereby disrupts the trophoblast functions on which a healthy pregnancy depends. The chain of evidence runs from human placental tissue through cell culture under oxidative stress to a mouse model and back again, with pharmacological rescue at the endpoint. Few studies of preeclampsia have traced a causal pathway with this degree of molecular resolution, and the identification of an epitranscriptomic mechanism in the disorder opens a fresh dimension in a field long dominated by angiogenic factors and immune hypotheses.

The therapeutic implications are tantalizing, though tempered by the usual caveats of early-stage research. Both nodes of the axis offer potential points of intervention: inhibiting ALKBH5 activity or blocking FPR2 signaling with agents such as WRW4 could, in theory, restore trophoblast function before the maternal syndrome takes hold. Because FPR2 already has known pharmacological modulators, the receptor represents a particularly attractive druggable target, and repurposing efforts could accelerate translation. Yet significant hurdles remain. The mouse model recapitulates preeclampsia-like features but not the full human disease, the precise timing and cell types in which the axis operates during human placentation require further mapping, and any intervention in pregnancy demands an exceptionally high safety bar. Still, the study adds a powerful new concept to the preeclampsia literature: that the fate of a pregnancy may hinge not on which genes are present, but on how long their RNA messages endure. As m6A biology continues to reshape our understanding of human disease, the placenta has now joined the list of organs where the epitranscriptome writes, and erases, the story of health.

Subject of Research: The role of the m6A demethylase ALKBH5 and its downstream target FPR2 in the pathogenesis of preeclampsia

Article Title: ALKBH5 contributes to preeclampsia through m6A-dependent upregulation of FPR2

Article References: Fan, C., Zhang, C., Liu, L., & Zhang, M. (2026). ALKBH5 contributes to preeclampsia through m6A-dependent upregulation of FPR2. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06471-z

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06471-z

Keywords: preeclampsia, ALKBH5, FPR2, m6A, RNA methylation, epitranscriptomics, trophoblast, placenta, oxidative stress, RNA stability, pregnancy, molecular biology

Unlike DNA methylation or histone modification, m6A operates directly on the transcript. It is installed by a writer complex whose catalytic core consists of METTL3 and METTL14, together with accessory factors such as WTAP and VIRMA, and it uses S-adenosylmethionine as the methyl donor. The mark can be removed by erasers—principally the demethylases FTO and ALKBH5—and its consequences are interpreted by reader proteins of the YTH domain family, including YTHDF1, YTHDF2, YTHDF3 and the YTHDC proteins, along with other RNA-binding proteins such as IGF2BP and hnRNPs. Because the methylation event is reversible and does not depend on a fixed sequence motif in the way DNA methylation does, it gives cells a fast, dynamic way to adjust the fate of thousands of transcripts at once. Through these players, m6A influences nearly every stage of an RNA molecule’s life: where it is spliced, whether it exits the nucleus, how long it survives, and how efficiently it is translated into protein.

The review’s central thesis is that dysregulated m6A methylation does not act on random genes. Instead, it converges on the core hallmarks of cancer. In many tumor types, elevated METTL3 stabilizes or boosts translation of oncogenic transcripts such as MYC, pushing cells into sustained proliferation. The same machinery can promote epithelial-mesenchymal transition, the program by which cancer cells become motile and invasive, by modifying transcripts for matrix metalloproteinases, TGF-β pathway components and other regulators of the extracellular matrix, thereby facilitating metastasis. Metabolic rewiring, another hallmark, is also under m6A control: the modification influences hypoxia signaling through HIF-1α and alters lipid and glucose metabolism genes, allowing tumors to adapt to the nutrient-poor, oxygen-starved conditions inside growing masses.

Equally striking is the modification’s grip on cell death pathways. The authors detail how m6A regulators modulate apoptosis—through transcripts such as BCL2, BAX and PUMA—autophagy, via targets including ULK1 and other ATG genes, and increasingly, ferroptosis, the iron-dependent form of cell death governed by factors such as SLC7A11 and GPX4. By tipping the balance of these transcripts, aberrant m6A labeling helps cancer cells survive stresses that would kill a normal cell, from chemotherapy-induced damage to oxidative assault. The review also emphasizes that the same regulator can play opposite roles depending on context: METTL3, for example, acts oncogenic in many carcinomas but has been reported to suppress tumor growth in others, a duality the authors attribute to differences in the target transcript landscape, tissue origin and cellular state.

Beyond the tumor cell itself, the review devotes substantial attention to the tumor immune microenvironment, an area where epitranscriptomics has produced some of its most clinically resonant findings. m6A modification shapes the function of dendritic cells, T cells, natural killer cells, tumor-associated macrophages, myeloid-derived suppressor cells and regulatory T cells, each of which must be precisely balanced for an effective anti-tumor response. When m6A regulators are perturbed, that balance tips toward immune evasion. The modification also directly controls the abundance of immune checkpoint molecules, including PD-L1, the target of a blockbuster class of immunotherapy drugs. In several cancer models, loss of the METTL3–METTL14 complex reduces PD-L1 expression and sensitizes tumors to immune attack, while in other settings erasers such as FTO exert the opposite effect on antitumor immunity—again underscoring the context dependence that pervades this field.

These mechanistic insights carry prognostic weight. The review surveys studies linking expression levels of individual writers, erasers and readers to overall survival, disease-specific survival, progression-free and recurrence-free survival across tumor types, from hepatocellular carcinoma and lung adenocarcinoma to colorectal and pancreatic cancers and acute myeloid leukemia. Aberrant expression of m6A regulators correlates with clinicopathological features such as tumor-node-metastasis stage, and multi-gene signatures built from these regulators show discriminative power in receiver operating characteristic analyses. Data resources such as The Cancer Genome Atlas have been instrumental here, allowing researchers to connect copy number variations and expression changes in m6A genes with patient outcomes. The authors suggest that m6A regulators could serve not only as biomarkers but as stratification tools that predict which patients will benefit from particular therapies, including immune checkpoint inhibitors.

Therapeutic resistance is another arena where the modification leaves fingerprints. The review describes how m6A dynamics influence responses to chemotherapy, targeted agents and radiotherapy by altering the stability of transcripts involved in drug efflux, DNA repair and stress survival. In some cancers, high METTL3 activity protects cells from cisplatin and other cytotoxic drugs; in others, demethylase activity confers resistance by stabilizing survival transcripts. Because immune checkpoint inhibitor response is also modulated through m6A-dependent control of checkpoint ligands and immune cell differentiation, the authors propose that combining m6A-targeted drugs with immunotherapy could convert immunologically cold tumors into responsive ones—a hypothesis supported by preclinical synergy data highlighted in the review.

Translating these observations into drugs is now a major focus. Small-molecule inhibitors of METTL3 have entered development, and inhibitors of FTO have shown activity in acute myeloid leukemia models by restoring tumor-suppressive transcript stability. The authors also discuss emerging modalities such as proteolysis-targeting chimeras, or PROTACs, which degrade rather than inhibit target proteins, and CRISPR-based systems using deactivated Cas13 that can be programmed to remove or install m6A marks at specific transcripts with single-gene precision. Detection technologies have advanced in parallel: methylated RNA immunoprecipitation sequencing, individual-nucleotide-resolution crosslinking methods, glyoxal- and nitrite-mediated sequencing, and single-base elongation- and ligation-based qPCR now allow researchers to map and quantify the modification with increasing resolution, while liquid chromatography-tandem mass spectrometry provides global quantification.

The review is candid about the obstacles standing between this biology and routine clinical practice. Delivering RNA-modifying drugs to the right cells remains the central challenge; lipid nanoparticles, the delivery platform behind mRNA vaccines, are one candidate solution, and small interfering RNA approaches are being explored to silence specific m6A regulators in tumors. Selectivity is another concern, since many m6A substrates are essential for normal tissue function, raising the specter of toxicity. The context-dependent, sometimes contradictory roles of individual regulators mean that therapies will likely need to be matched to tumors in which a given regulator acts oncogenically, reinforcing the push toward personalized oncology. The authors also note that non-coding RNAs—circular RNAs, long non-coding RNAs and microRNA precursors—carry their own m6A marks, adding layers of regulation that are only beginning to be mapped.

What emerges from this synthesis is a picture of cancer as a disease of information as much as of genes. The genome may be intact, but the chemical annotations on its transcripts can be rewritten in ways that produce a malignant phenotype. With the writer, eraser and reader machinery now genetically and pharmacologically tractable, and with immunotherapy providing a clinically validated partner, the m6A axis offers a rare combination of mechanistic depth and therapeutic proximity. The review by Tang and colleagues, published open access in Molecular Cancer, positions aberrant RNA methylation as a frontier where epitranscriptomics, tumor immunology and drug development converge—and where the next decade of cancer research is likely to unfold.

Subject of Research: The role of aberrant N6-methyladenosine RNA modification in cancer progression, immune evasion and therapy

Article Title: The role and clinical impact of aberrant m6A RNA modification in cancer

Article References: Tang, S., Xie, R., Fu, J., Wen, L., Guo, H., Tang, S., Liu, T., Hu, H., Ji, D., Jiang, X., Wang, J., Wang, C., Wang, S., Yang, Y., Liu, C., Yang, Y., Zhou, J., Yu, L., & Zhou, H. (2026). The role and clinical impact of aberrant m6A RNA modification in cancer. Molecular Cancer. https://doi.org/10.1186/s12943-026-02775-7

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02775-7

Keywords: m6A, N6-methyladenosine, RNA modification, epitranscriptomics, METTL3, FTO, ALKBH5, cancer hallmarks, immune evasion, PD-L1, targeted therapy, tumor microenvironment

Asthma affects hundreds of millions of people worldwide and has long been known to run in families, but the majority of the genetic variants linked to the disease sit in stretches of DNA that do not code for proteins. This so-called missing heritability has frustrated researchers for decades, because it is difficult to know which of these non-coding variants actually change how immune cells behave. The team behind the new study approached the problem from an unusual angle. Rather than asking which variants sit near genes, they asked which variants fall inside or near the chemical docking sites for m6A, the most abundant internal modification found in eukaryotic messenger RNA. These sites are called m6A-SNPs, and emerging evidence suggests they can influence how messenger RNA molecules are read, stabilized, and translated, thereby altering protein output without changing the underlying protein sequence.

To find m6A-regulated genes that matter in asthma, the researchers integrated genome-wide association study data from the UK Biobank, covering both asthma diagnoses and measures of lung function such as forced expiratory volume in one second, forced vital capacity, and peak expiratory flow, with a catalog of m6A-associated variants drawn from the m6AVar database. They then used summary-data-based Mendelian randomization, a statistical framework that borrows genetic variants as instruments to infer whether altered gene expression is a cause or merely a consequence of disease, along with expression quantitative trait loci summary statistics from the Westra and CAGE datasets. This triangulation allowed them to prioritize candidate genes in which genetic variation plausibly changes expression in a way that contributes to asthma risk or impaired lung function.

The analysis converged on TET2, a gene encoding ten-eleven translocation methylcytosine dioxygenase 2, an enzyme best known for its role in DNA demethylation and for its profound influence on innate immune cells. In the study’s genetic models, TET2 was associated not only with asthma susceptibility but also with lung function traits, making it one of the few candidates that satisfied evidence criteria across both disease and physiological endpoints. Importantly, the association passed correction for multiple testing at a false discovery rate threshold, indicating that the signal was unlikely to arise by chance despite the enormous number of variants and genes tested.

Genetic prioritization alone cannot reveal where in the body, or in which cells, the effect takes place, so the team turned to single-cell RNA sequencing of tissue from an ovalbumin-induced mouse model of allergic asthma. This technology profiles the gene expression of thousands of individual cells at once, allowing researchers to map which cell types change their molecular identity as disease develops. The single-cell analysis showed that TET2 was selectively upregulated in monocytes during asthmatic inflammation, and that the monocytes themselves displayed hallmarks of inflammatory activation, including enrichment of pro-inflammatory gene programs and activation of the PI3K signaling pathway, a cellular communication cascade with well-established roles in immune cell survival, migration, and cytokine production. Other immune populations, including T helper cells and tissue-resident memory T cells, showed distinct disease-associated changes, but the monocyte-centered pattern of TET2 upregulation stood out as the most consistent finding linked to the genetic signal.

With TET2 identified as the prime suspect, the researchers moved to mechanistic experiments to determine how the gene is controlled during inflammation. When monocytes were exposed to inflammatory stimulation with lipopolysaccharide, levels of the m6A demethylase ALKBH5 rose. This enzyme chemically removes m6A marks from target messenger RNAs. The team found that inflammatory induction of ALKBH5 led to a reduction in m6A modification of TET2 messenger RNA, which in turn increased TET2 protein levels. Using m6A RNA immunoprecipitation to quantify the modification directly, they confirmed that the m6A mark on TET2 transcript was diminished in the presence of ALKBH5, and that wild-type ALKBH5, but not a demethylase-deficient mutant, produced this effect. The result establishes a concrete regulatory loop: inflammation induces ALKBH5, ALKBH5 strips m6A from TET2 messenger RNA, and more TET2 protein accumulates in the cell.

The downstream consequences were equally clear. Elevated TET2 protein activated PI3K/AKT signaling, measurable by increased levels of phosphorylated AKT, and boosted production of pro-inflammatory cytokines, the chemical messengers that recruit and intensify immune responses in the airways. Crucially, the researchers showed that interrupting the pathway at either end, by knocking down TET2 with small interfering RNA or by suppressing ALKBH5, attenuated both the signaling activation and the cytokine output. These loss-of-function experiments provide the strongest evidence yet that the ALKBH5-m6A-TET2 axis is not merely correlated with monocyte inflammation but is functionally required for it.

The implications of the study reach in several directions at once. For asthma genetics, it offers a concrete example of how a non-coding variant can exert its influence by altering an epitranscriptomic modification site rather than a protein-coding sequence, a mechanism that could explain a meaningful share of the missing heritability in asthma and other immune diseases. For immunology, it adds asthma to the growing list of inflammatory conditions in which RNA methylation dynamically reprograms innate immune cells, and it situates TET2, already famous for its roles in leukemia, cardiovascular disease, and clonal hematopoiesis, at the center of a respiratory inflammatory pathway. The involvement of monocytes is particularly relevant to patients with severe or neutrophilic asthma, in whom steroid responses are often poor and innate immune cells are thought to drive much of the disease burden.

Most tantalizing is the therapeutic possibility. Because ALKBH5 acts upstream of TET2 in this pathway, inhibiting ALKBH5 could, in principle, restore m6A marks on TET2 messenger RNA, reduce TET2 protein levels, and calm the overactive PI3K/AKT-driven inflammatory program in monocytes without broadly suppressing the immune system. The authors caution that their findings rest on genetic association, single-cell profiling, and cell-culture experiments, and that validation in patient samples and animal models will be needed before the ALKBH5-m6A-TET2 axis can be considered a drug target. Nevertheless, the study provides a complete narrative arc, from a population-level genetic signal to a molecular mechanism inside individual immune cells, and it does so with an analytical strategy that other researchers can apply to the many complex diseases whose genetics remain stubbornly unexplained. As the cost of single-cell sequencing falls and catalogs of RNA modification sites continue to expand, the approach demonstrated here is likely to be repeated across a widening range of conditions, potentially converting thousands of obscure genetic associations into actionable biological insights.

Subject of Research: Epitranscriptomic regulation of monocyte inflammatory activation in asthma via the ALKBH5-m6A-TET2 axis and PI3K signaling

Article Title: TET2 promotes monocyte inflammatory activation in asthma via ALKBH5-m6A regulation and PI3K signaling: evidence from m6A-SNP and single-cell analyses

Article References: Wang, Z., Wang, Q., Sa, Y., Ma, N., Wang, S., Huang, C., Liu, M., & Tang, S. (2026). TET2 promotes monocyte inflammatory activation in asthma via ALKBH5-m6A regulation and PI3K signaling: evidence from m6A-SNP and single-cell analyses. Molecular Genetics and Genomics, 301(1), Article 190. https://doi.org/10.1007/s00438-026-02497-x

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02497-x

Keywords: asthma, TET2, ALKBH5, m6A modification, monocytes, PI3K/AKT signaling, GWAS, m6A-SNP, single-cell RNA sequencing, airway inflammation, epitranscriptomics, genetic susceptibility

The study, led by Yinliang Zhang, Xiaochen Gai, Dong Zhao and Yongsheng Chang, with contributions from a team at Tianjin Medical University, Capital Medical University and Westlake University, began with a deceptively simple observation. When mice were exposed to cold, or when their fat cells were bathed in norepinephrine, the sympathetic neurotransmitter that surges during cold exposure, levels of ALKBH5 rose sharply in brown and subcutaneous fat. ALKBH5 belongs to a small family of enzymes that remove N6-methyladenosine, or m6A, the most abundant internal chemical modification on messenger RNA. By stripping these methyl marks, ALKBH5 can alter how long particular mRNA molecules survive before being degraded, and therefore how much protein the cell can manufacture from them.

Tracing the signal upstream, the investigators found that ALKBH5 expression is not a passive side effect of cold. Instead, norepinephrine binding to adrenergic receptors triggers the classic thermogenic signaling cascade: cyclic AMP accumulates, protein kinase A is activated, and the transcription factor CREB is phosphorylated and dispatched to the ALKBH5 gene, switching it on. Pharmacological tools confirmed the pathway’s logic. Forskolin and CW 008, which elevate cAMP signaling, boosted ALKBH5 expression in both mouse and human adipocytes, while the CREB inhibitor 666-15 and the PKA inhibitor H89 blunted that induction. In other words, the same sympathetic signal that commands fat cells to burn also instructs them to reprogram their RNA landscape.

The consequences of losing that reprogramming became clear when the team generated mice lacking ALKBH5 specifically in adipose tissue. Both male and female animals showed reduced thermogenic capacity, dropping their body temperature faster during acute cold exposure and dissipating less energy overall. When fed a high-fat diet, the knockout mice gained more weight, accumulated more fat mass and developed impaired glucose homeostasis compared with controls. Crucially, the metabolic defect appeared without changes in food intake or locomotor activity, pointing squarely at energy expenditure rather than appetite as the underlying problem. The findings applied across sexes, strengthening the physiological relevance of the pathway.

The mirror-image experiment proved equally striking. When the researchers delivered an ALKBH5 gene into brown and subcutaneous fat using adeno-associated virus, the treated animals became metabolic overachievers. They maintained higher core body temperatures in the cold, generated greater total energy expenditure, and resisted the weight gain and glucose intolerance induced by a high-fat diet. Human data added a correlative dimension: analysis of gene expression from public cohorts, including the Genotype-Tissue Expression project, showed that ALKBH5 levels in human subcutaneous fat inversely correlate with obesity, suggesting that the mouse findings may translate to human biology.

The deepest insight, however, came from the mechanistic work. Searching for the thermogenic machinery that ALKBH5 controls, the team landed on CKB, creatine kinase B, an enzyme central to the so-called futile creatine cycle. In this circuit, creatine kinase pumps phosphate onto creatine to build phosphocreatine, and a mitochondrial enzyme hydrolyzes it back again, forcing the cell to burn ATP in a loop that generates heat rather than useful work. Deleting ALKBH5 from fat lowered CKB expression and creatine kinase activity, while boosting ALKBH5 raised them. When the researchers depleted creatine with beta-guanidinopropionic acid, the thermogenic benefits of ALKBH5 overexpression largely evaporated, confirming that creatine metabolism is the load-bearing element of the pathway.

Molecularly, the connection between the demethylase and the creatine kinase is an elegant piece of RNA biology. ALKBH5 removes m6A marks from the CKB transcript itself. Those methyl tags, when present, are recognized by YTHDF2, a reader protein that escorts methylated mRNAs to degradation machinery. By demethylating CKB mRNA, ALKBH5 shields it from YTHDF2-mediated destruction, lengthening the transcript’s half-life and allowing more creatine kinase B protein to be produced. Experiments with mutated CKB constructs, methylated RNA immunoprecipitation, and YTHDF2 knockdown in both mouse brown and human beige adipocytes pieced this mechanism together site by site, and the m6A peaks identified on CKB mRNA matched the canonical DRACH sequence motifs predicted from genomic analysis.

Perhaps the most provocative result concerns UCP1, the long-reigning icon of thermogenesis. In mice genetically engineered to lack UCP1 entirely, ALKBH5 overexpression still raised energy expenditure and protected against cold exposure, demonstrating that the creatine-driven pathway operates in parallel with, and independently of, the classical uncoupling mechanism. This echoes recent single-cell studies suggesting that thermogenic fat contains distinct subpopulations of cells, some defined by UCP1 and others by futile cycling enzymes. The new work provides the first known regulatory link between an adrenergic signal and the creatine branch, effectively giving that parallel pathway its own commander.

The therapeutic implications are considerable. Obesity treatments based on increasing energy expenditure have long sought safe ways to activate thermogenic fat, but UCP1-centric strategies face hurdles, including uncertainty about how much functional brown fat adult humans carry and concerns about off-target adrenergic stimulation. A target that works through mRNA stabilization rather than receptor agonism, and that functions even without UCP1, opens a genuinely different door. The authors caution that ALKBH5 is a broad-acting demethylase implicated in diverse processes, from fertility to cancer metabolism to cardiac fibrosis, so any obesity therapy built on it would need careful tissue specificity. Still, the demonstration that a single RNA modification enzyme can rewire cellular fuel chemistry in response to cold reframes thermogenesis as an epitranscriptomic phenomenon, and it hands obesity researchers a new molecular lever precisely where they need it most: the fat that burns.

Subject of Research: The role of the m6A demethylase ALKBH5 in regulating creatine-driven non-shivering thermogenesis in adipose tissue

Article Title: ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold

Article References: Zhang, Y., Du, C., Qiao, W., Qiu, P., Xu, C., Yang, X., Hao, J., Zhao, D., Gai, X., & Chang, Y. (2026). ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold. Nature Metabolism. https://doi.org/10.1038/s42255-026-01592-y

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01592-y

Keywords: ALKBH5, thermogenesis, brown fat, m6A methylation, CKB, creatine kinase, UCP1, obesity, YTHDF2, norepinephrine, CREB signaling, metabolism